Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

Unsupervised_Clustering_Project/ ├── data_loader.py # Loads the dataset ├── clustering.py # Handles KMeans and silhouette scoring ├── visualize.py # Creates scatter, elbow, and pair plots ├── main.py ...